Earlier quoted context omitted.
The main point that beagle3 makes is that the Pfizer study actually shows ~89% efficacy starting 12 days after the first dose, which improves to ~90% immediately after the 2nd dose (day 21) and ~95% 7 days later (day 28). The Maccabi study was designed with this comparison in mind: they look at efficacy in days 1-12 and 13-24 after the first dose. They are mainly interested in comparing the Pfizer results for days 13…
You are correct, but this doesn't show a conspiracy like a certain other commenter hints at. We always knew that the the Pfizer vaccine has a lower chance of preventing transmissions, the original treatment regime was two doses, and we further know that the Pfizer vaccine wasn't originally tested vs B117 and the other mutations and it's quite possible it has lower efficiency vs those. Still, there's a good chance two…
The political rather than medical decision making in Israel is out in the open, there’s no need for conspiracies.
It took @RanBalicer 3 days to acknowledge the abysmal data, and it was not “gee, we might have made a mistake in the model”, it’s always “an unexpected twist in the mutation/behaviour/population”. It is beyond embarrassing. But I digress.
Let’s just agree that the 95% RRR for “reported mild symptoms” is meaningless, and that the 50% number from Maccabi is actually good news, and we should use that number in models and predictions?